Characteristics of adverse drug reactions induced by flutamide and bicalutamide: a real-world pharmacovigilance study using FAERS

References

• Heczko D, Hachuła B, Maksym P, et al. The effect of various poly (n-vinylpyrrolidone) (PVP) polymers on the crystallization of flutamide. Pharmaceuticals (Basel). 2022;15(8):971. doi: 10.3390/ph15080971
   PubMedGoogle Scholar
• Brogden RN, Clissold SF. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989;38(2):185–203. doi: 10.2165/00003495-198938020-00003
   PubMed Web of Science ®Google Scholar
• Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer. A review. Drugs Aging. 1998;12(5):401–422. doi: 10.2165/00002512-199812050-00006
   PubMed Web of Science ®Google Scholar
• Kakutani N, Iwai T, Ohno Y, et al. Evaluation of covalent binding of flutamide and its risk assessment using (19)F-NMR. Xenobiotica. 2021;51(1):88–94. doi: 10.1080/00498254.2020.1817626
   PubMed Web of Science ®Google Scholar
• Jones CU, Pugh SL, Sandler HM, et al. Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. Int J Radiat Oncol Biol Phys. 2022;112(2):294–303. doi: 10.1016/j.ijrobp.2021.08.031
   PubMed Web of Science ®Google Scholar
• Giorgetti R, di Muzio M, Giorgetti A, et al. Flutamide-induced hepatotoxicity: ethical and scientific issues. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):69–77.
   PubMedGoogle Scholar
• Wu B, Shen P, Yin X, et al. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2023;89(2):440–448. doi: 10.1111/bcp.15336
   PubMed Web of Science ®Google Scholar
• Higashiyama A, Yokoyama T, Omoto Y, et al. Flutamide-induced photoleukomelanoderma. J Dermatol. 2016;43(9):1105–1106. doi: 10.1111/1346-8138.13340
   PubMed Web of Science ®Google Scholar
• Turkkan G, Dogan C, Tek B. Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: a case report. J Oncol Pharm Pract. 2020;26(4):1029–1031. doi: 10.1177/1078155219886918
   PubMed Web of Science ®Google Scholar
• Ding Y, Ma H, Xu Y, et al. Potentiation of flutamide-induced hepatotoxicity in mice by Xian-Ling-Gu-Bao through induction of CYP1A2. J Ethnopharmacol. 2021;278:114299. doi: 10.1016/j.jep.2021.114299
   PubMed Web of Science ®Google Scholar
• Kato R, Yamada T, Noda T, et al. Mechanism of non-steroidal anti-androgen-induced liver injury: reactive metabolites of flutamide and bicalutamide activate inflammasomes. Toxicol Vitro. 2023;90:105606. doi: 10.1016/j.tiv.2023.105606
   PubMed Web of Science ®Google Scholar
• Egberts AC, Meyboom RH, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 2002;25(6):453–458. doi: 10.2165/00002018-200225060-00010
   PubMed Web of Science ®Google Scholar
• Shiraishi C, Hirai T, Ogura T, et al. Analysis of clinical factors in olaparib-related anemia using adverse drug event reporting databases. Anticancer Res. 2023;43(2):883–891. doi: 10.21873/anticanres.16231
   PubMed Web of Science ®Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21(4):563–572. doi: 10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Yan YD, Zhao Y, Zhang C, et al. Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine. 2022;50:101535. doi: 10.1016/j.eclinm.2022.101535
   PubMedGoogle Scholar
• Sarıkaya S, Resorlu M, Oguz U, et al. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature. Arch Ital Urol Androl. 2014;86(4):288–290. doi: 10.4081/aiua.2014.4.288
   PubMedGoogle Scholar
• Pontiroli L, Sartori M, Pittau S, et al. Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms. Ital J Gastroenterol Hepatol. 1998;30(3):310–314.
   PubMed Web of Science ®Google Scholar
• Osculati A, Castiglioni C. Fatal liver complications with flutamide. Lancet. 2006;367(9517):1140–1141. doi: 10.1016/S0140-6736(06)68498-5
   PubMed Web of Science ®Google Scholar
• Zhang L, Guo J, Zhang Q, et al. Flutamide induces hepatic cell death and mitochondrial dysfunction via inhibition of NRF2-mediated heme oxygenase-1. Oxid Med Cell Longev. 2018;2018:8017073. doi: 10.1155/2018/8017073
   PubMed Web of Science ®Google Scholar
• Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–136. doi: 10.1016/j.ejca.2019.04.031
   PubMed Web of Science ®Google Scholar
• Huang WK, Liu CH, Pang ST, et al. Type of androgen deprivation therapy and risk of dementia among patients with prostate cancer in Taiwan. JAMA Netw Open. 2020;3(8):e2015189. doi: 10.1001/jamanetworkopen.2020.15189
   PubMed Web of Science ®Google Scholar
• Daniels J, Brickstock A, Charlton R. Gynaecomastia. BMJ. 2022;379:e069771. doi: 10.1136/bmj-2021-069771
   PubMedGoogle Scholar
• Di Lorenzo G, Autorino R, Perdona S, et al. Management of gynecomastia in patients with prostate cancer: a systematic review. Lancet Oncol. 2005;6(12):972–979. doi: 10.1016/S1470-2045(05)70464-2
   PubMed Web of Science ®Google Scholar
• Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology. 1997;50(6):929–933. doi: 10.1016/S0090-4295(97)00457-3
   PubMed Web of Science ®Google Scholar
• Innocenti A, Serena G, Innocenti M. External quilting: new technique to avoid hematoma in gynecomastia surgery. Aesthetic Plast Surg. 2021;45(2):831–832. doi: 10.1007/s00266-020-01734-x
   PubMed Web of Science ®Google Scholar
• Kokorovic A, So AI, Serag H, et al. UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: adverse events and management strategies. Can Urol Assoc J. 2022;16(8):E416–E431. doi: 10.5489/cuaj.8054
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhu S, Hu Q, et al. Hemolytic anemia induced by flutamide: a case report. Eur J Hosp Pharm. 2023;30(e1):e109–e111. doi: 10.1136/ejhpharm-2021-002936
   PubMedGoogle Scholar
• Voegeli TA, Kurtz A, Grimm MO, et al. Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system. Horm Metab Res. 2005;37(2):89–93. doi: 10.1055/s-2005-861172
   PubMed Web of Science ®Google Scholar
• Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–192. doi: 10.1038/aja.2011.102
   PubMed Web of Science ®Google Scholar